Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968150 | 0.84 | SIGMAR1 (0.47) | SIGMAR1PARP1ALDH1A1MEN1KMT2A | |
| SCHEMBL968613 | 0.82 | SIGMAR1 (0.45) | SIGMAR1PARP1ALDH1A1KDM4EHRH3 | |
| SCHEMBL969809 | 0.79 | HRH3 (0.39) | SIGMAR1HRH3 | |
| SCHEMBL970610 | 0.78 | SIGMAR1 (0.40) | SIGMAR1PARP1ALDH1A1MEN1KMT2A | |
| SCHEMBL971572 | 0.78 | HRH3 (0.41) | SIGMAR1PARP1ALDH1A1HTTNPSR1 | |
| SCHEMBL1016931 | 0.78 | PARP1 (0.41) | SIGMAR1PARP1ALDH1A1MEN1KMT2A | |
| SCHEMBL967063 | 0.77 | SIGMAR1 (0.41) | SIGMAR1PARP1ALDH1A1MEN1KMT2A | |
| SCHEMBL970851 | 0.75 | SIGMAR1 (0.46) | SIGMAR1PARP1ALDH1A1HTTNPSR1 | |
| SCHEMBL971655 | 0.75 | SIGMAR1 (0.47) | SIGMAR1PARP1ALDH1A1MEN1KMT2A | |
| SCHEMBL968574 | 0.75 | SIGMAR1 (0.47) | SIGMAR1PARP1ALDH1A1HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110002855-A1 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110002855-A1 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110002855-A1 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002855-A1 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | HRH3, HRH4, HRH1 | SIGMAR1 82/4885PARP1 2898/4885ALDH1A1 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.